Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capaci...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00835/full |
_version_ | 1819263605470658560 |
---|---|
author | Flore Gouel Anne-Sophie Rolland Jean-Christophe Devedjian Thierry Burnouf Thierry Burnouf Thierry Burnouf David Devos David Devos |
author_facet | Flore Gouel Anne-Sophie Rolland Jean-Christophe Devedjian Thierry Burnouf Thierry Burnouf Thierry Burnouf David Devos David Devos |
author_sort | Flore Gouel |
collection | DOAJ |
description | Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system—e.g., development, plasticity, maintenance, neurogenesis—neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease. |
first_indexed | 2024-12-23T20:16:15Z |
format | Article |
id | doaj.art-315ab431f7f8454d821621d82fbcc187 |
institution | Directory Open Access Journal |
issn | 1664-2295 |
language | English |
last_indexed | 2024-12-23T20:16:15Z |
publishDate | 2019-08-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Neurology |
spelling | doaj.art-315ab431f7f8454d821621d82fbcc1872022-12-21T17:32:40ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-08-011010.3389/fneur.2019.00835455919Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet LysatesFlore Gouel0Anne-Sophie Rolland1Jean-Christophe Devedjian2Thierry Burnouf3Thierry Burnouf4Thierry Burnouf5David Devos6David Devos7Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceDepartment of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceDepartment of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, TaiwanInternational PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, TaiwanInternational PhD Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanDepartment of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceDepartment of Neurology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system—e.g., development, plasticity, maintenance, neurogenesis—neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.https://www.frontiersin.org/article/10.3389/fneur.2019.00835/fullAmyotrophic lateral sclerosisgrowth factorstherapeuticstem cellhuman platelet lysate |
spellingShingle | Flore Gouel Anne-Sophie Rolland Jean-Christophe Devedjian Thierry Burnouf Thierry Burnouf Thierry Burnouf David Devos David Devos Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates Frontiers in Neurology Amyotrophic lateral sclerosis growth factors therapeutic stem cell human platelet lysate |
title | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates |
title_full | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates |
title_fullStr | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates |
title_full_unstemmed | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates |
title_short | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates |
title_sort | past and future of neurotrophic growth factors therapies in als from single neurotrophic growth factor to stem cells and human platelet lysates |
topic | Amyotrophic lateral sclerosis growth factors therapeutic stem cell human platelet lysate |
url | https://www.frontiersin.org/article/10.3389/fneur.2019.00835/full |
work_keys_str_mv | AT floregouel pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates AT annesophierolland pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates AT jeanchristophedevedjian pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates AT thierryburnouf pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates AT thierryburnouf pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates AT thierryburnouf pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates AT daviddevos pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates AT daviddevos pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates |